Literature DB >> 11173570

Modulation of Multidrug Resistance in Cancer by Immunosuppresive Agents. Preclinical Studies.

Adorján Aszalos1.   

Abstract

This is a brief summary of the status of known immunosuppressive drugs describing their potential and mode of action to reverse the function of the MDR1 gene product, the P glycoprotein. Different aspects of these immunosuppressors have been reviewed in the recent literature. This summary will focus only on those studies which relate to the effect of these drugs on the P-glycoprotein. In addition, studies which may explain the mode of action, but do not deal directly with P-glycoprotein, are also summarized.

Entities:  

Year:  1995        PMID: 11173570     DOI: 10.1007/bf02893586

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  50 in total

1.  Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b.

Authors:  L M Greenberger; C J Lisanti; J T Silva; S B Horwitz
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

2.  Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals.

Authors:  R K Burt; S Garfield; K Johnson; S S Thorgeirsson
Journal:  Carcinogenesis       Date:  1988-12       Impact factor: 4.944

3.  Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.

Authors:  B M Foxwell; A Mackie; V Ling; B Ryffel
Journal:  Mol Pharmacol       Date:  1989-10       Impact factor: 4.436

4.  Cyclosporin A inhibits protein kinase C activity: a contributing mechanism in the development of nephrotoxicity?

Authors:  R J Walker; V A Lazzaro; G G Duggin; J S Horvath; D J Tiller
Journal:  Biochem Biophys Res Commun       Date:  1989-04-14       Impact factor: 3.575

5.  Interaction of forskolin with the P-glycoprotein multidrug transporter.

Authors:  D I Morris; L A Speicher; A E Ruoho; K D Tew; K B Seamon
Journal:  Biochemistry       Date:  1991-08-27       Impact factor: 3.162

6.  P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

Authors:  T P Miller; T M Grogan; W S Dalton; C M Spier; R J Scheper; S E Salmon
Journal:  J Clin Oncol       Date:  1991-01       Impact factor: 44.544

7.  Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells.

Authors:  T Skovsgaard
Journal:  Cancer Res       Date:  1978-12       Impact factor: 12.701

8.  Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers.

Authors:  A R Safa; C J Glover; J L Sewell; M B Meyers; J L Biedler; R L Felsted
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

9.  Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

Authors:  R F Ozols; R E Cunnion; R W Klecker; T C Hamilton; Y Ostchega; J E Parrillo; R C Young
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

10.  Interaction of multidrug-resistant Chinese hamster ovary cells with amphiphiles.

Authors:  D W Loe; F J Sharom
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.